Clinical research/Pharmaceutical History of Medicine May 2024 A Brief History of Antimicrobial Resistance Devin Hunt and Olivia S. Kates, MD, MA Resistance has dogged infectious disease treatment processes since we started using modern antimicrobials. AMA J Ethics. 2024;26(5):E408-417. doi: 10.1001/amajethics.2024.408. Case and Commentary May 2024 How Should We Manage Antimicrobial Resistance in Resource-Limited Settings? Elizabeth A. Gulleen, MD and Margaret Lubwama, MBChB, MMed Patients living in low-and middle-income countries (LMICs) shoulder the greatest burden of infections caused by antimicrobial-resistant pathogens. AMA J Ethics. 2024;26(5):E373-379. doi: 10.1001/amajethics.2024.373. Medicine and Society Oct 2023 What Might Aducanumab Teach Us About Clinicians’ Judgment About Whether to Recommend Emerging Alzheimer’s Interventions? Adam W. Burroughs, MD and Lewis P. Krain, MD Ethics questions about care of patients with AD could influence clinicians’ judgment about whether and when to recommend aducanumab. AMA J Ethics. 2023;25(10):E777-782. doi: 10.1001/amajethics.2023.777. Viewpoint May 2022 Reimagining Roles of Dietary Supplements in Psychiatric Care Katherine Wu, MD and Erik Messamore, MD, PhD Government-supported review and safety monitoring is needed for dietary supplements’ use in the care of patients with mental illness. AMA J Ethics. 2022;24(5):E437-442. doi: 10.1001/amajethics.2022.437. Podcast May 2022 Author Interview: “Reimagining Roles of Dietary Supplements in Psychiatric Care” Dr Katherine Wu joins Ethics Talk to discuss her article, coauthored with Dr Erik Messamore: “Reimagining Roles of Dietary Supplements in Psychiatric Care.” Pagination First page « First Previous page ‹‹ Prev Page 1 Page 2 Current page 3
History of Medicine May 2024 A Brief History of Antimicrobial Resistance Devin Hunt and Olivia S. Kates, MD, MA Resistance has dogged infectious disease treatment processes since we started using modern antimicrobials. AMA J Ethics. 2024;26(5):E408-417. doi: 10.1001/amajethics.2024.408.
Case and Commentary May 2024 How Should We Manage Antimicrobial Resistance in Resource-Limited Settings? Elizabeth A. Gulleen, MD and Margaret Lubwama, MBChB, MMed Patients living in low-and middle-income countries (LMICs) shoulder the greatest burden of infections caused by antimicrobial-resistant pathogens. AMA J Ethics. 2024;26(5):E373-379. doi: 10.1001/amajethics.2024.373.
Medicine and Society Oct 2023 What Might Aducanumab Teach Us About Clinicians’ Judgment About Whether to Recommend Emerging Alzheimer’s Interventions? Adam W. Burroughs, MD and Lewis P. Krain, MD Ethics questions about care of patients with AD could influence clinicians’ judgment about whether and when to recommend aducanumab. AMA J Ethics. 2023;25(10):E777-782. doi: 10.1001/amajethics.2023.777.
Viewpoint May 2022 Reimagining Roles of Dietary Supplements in Psychiatric Care Katherine Wu, MD and Erik Messamore, MD, PhD Government-supported review and safety monitoring is needed for dietary supplements’ use in the care of patients with mental illness. AMA J Ethics. 2022;24(5):E437-442. doi: 10.1001/amajethics.2022.437.
Podcast May 2022 Author Interview: “Reimagining Roles of Dietary Supplements in Psychiatric Care” Dr Katherine Wu joins Ethics Talk to discuss her article, coauthored with Dr Erik Messamore: “Reimagining Roles of Dietary Supplements in Psychiatric Care.”
